A deeper understanding of the pathophysiology of ASXL1 and SRSF2 mutations may usher in an era of targeted therapies for patients with ASXL1/SRSF2-mutated MDS/AML. The gene discussed is SRSF2; the disease is myelodysplastic syndrome.